Journals / Anadolu Kardiyoloji Dergisi / 2014 / Cilt: 14 - Sayı: 2

Heart failure: a complex clinical process interpreted by systems biology approach and network medicine

Pages
178–185
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In heart failure, the recognition of molecular targets within the complex networks will increase the conceptual basis of pharmacology and the identification of novel biomarkers and at the same time will accelerate the discovery of new drugs. (Anadolu Kardiyol Derg 2014; 14: 178-85)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Systems biology is founded on the principles of integrative computational analysis and on the data from genetic and molecular components.
📊
Key Findings & Data:This characterization of heart failure has significant limitations to recognize preclinical disease features and to explain the progressive nature of the syndrome.
💡
Conclusion & Impact:In heart failure, the recognition of molecular targets within the complex networks will increase the conceptual basis of pharmacology and the identification of novel biomarkers and at the same time will accelerate the discovery of new drugs. (Anadolu Kardiyol Derg 2014; 14: 178-85)
🔬Design:Review & Systematic Survey
📍Scope:2014 Verileri
⚙️Variables:Domain Parameters

Abstract

Systems biology is founded on the principles of integrative computational analysis and on the data from genetic and molecular components. The integration of biological components produces interacting networks, modules and phenotypes with remarkable applications in the field of clinical medicine. The evolving concept of network medicine gives a more precise picture of the intrinsic complexity of failing myocardium and its clinical consequences. The present review is focused on the impact of network cardiology in explaining the progressive nature of the clini- cal syndrome of heart failure. The failing myocardium and the subsequent clinical syndrome of heart failure disclose a dynamical and non- linear system with a progressive picture of clinical deterioration. The classical description of heart failure is based on tissue pathology and clinical presentation, and lately on specific genetic and molecular modifications. This characterization of heart failure has significant limitations to recognize preclinical disease features and to explain the progressive nature of the syndrome. Systems biology detects and evaluates spe- cific networks from molecular, cellular and tissue elements, and assesses their influence on the appearance of clinical phenotypes. The clas- sical reductive concept of heart failure is inadequate to provide data for molecular dysfunctions or defective coordination of the intercon- nected network components that are central to the genesis and clinical deterioration of heart failure. In heart failure, the recognition of molecular targets within the complex networks will increase the conceptual basis of pharmacology and the identification of novel biomarkers and at the same time will accelerate the discovery of new drugs. (Anadolu Kardiyol Derg 2014; 14: 178-85)

🔖

Cite This Article

LOURIDAS, G. E., LOURIDA, K. G. (2022). Heart failure: a complex clinical process interpreted by systems biology approach and network medicine. Anadolu Kardiyoloji Dergisi, Cilt: 14 - Sayı: 2, 178–185. https://ajindex.com/articles/436089

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Kitano H. Systems biology: a brief overview. Science 2002
  2. [CrossRef] 2. Stolovitzky G, Kahlem P Califano A. The challenges of systems, biology: Ann. N Y Acad Sci 2009
  3. Weiss JN, Qu Z, Garfinkel A. Understanding biological complexity: lessons from the past. FASEB J 2003
  4. [CrossRef] 4. Watts DJ, Strogatz SH. Collective dynamics of ‘small-world’ networks. Nature 1998
  5. [CrossRef] 5. Osler W. The principles and practice of medicine. Appleton
  6. New York: 1892. 6. Loscalzo J, Kohane I, Barabasi AL. Human disease classification in the postgenomic era: a complex systems approach to human pathobiology. Mol Syst Biol 2007
  7. [CrossRef] 7. Loscalzo J, Barabasi AL. Systems biology and the future of medicine. Wiley Interdiscip Rev Syst Biol Med 2011
  8. [CrossRef] 8. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 2009
  9. [CrossRef] 9. Lipsky MS, Sharp LK. From idea to market: the drug approval process. J Am Board Fam Pract 2001
  10. Berger SI, Iyengar R. Network analyses in systems pharmacology. Bioinformatics 2009
  11. [CrossRef] 11. Sorger PK, Schoeberl B. An expanding role for cell biologists in drug discovery and pharmacology. Mol Biol Cell 2012
  12. [CrossRef] 12. Wang IM, Stone DJ, Nickle D, Loboda A, Puig O, Roberts C. Systems biology approach for new target and biomarker identification. Curr Top Microbiol Immunol 2013
  13. [CrossRef] 13. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 2005
  14. [CrossRef] 14. Clerico A, Recchia FA, Passino C, Emdin M. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol 2006
  15. [CrossRef] 15. Boogerd FC, Bruggeman FJ, Hofmeyr JHS, Westerhoff HV, ed. Systems Biology, Philosophical Foundations. Elsevier B.V. Oxford, UK, 2007. 16. Louridas GE, Lourida KG. A conceptual paradigm of heart failure and systems biology approach. Intern J Cardiol 2012
  16. [CrossRef] 17. Bruggeman FJ, Westerhoff HV. The nature of systems biology. Trends Microbiol 2007
  17. [CrossRef] 18. Jeong H, Tombor B, Albert R, Oltvai ZN, Barabasi AL. The large-scale organization of metabolic networks. Nature 2000
  18. [CrossRef] 19. Nadeau JH, Burrage LC, Restivo J, Pao YH, Churchill G, Hoit BD. Pleiotropy, hom